Expertise in
13
conditions

Dr. Andrew Evens

Hematology | Oncology
The Cancer Institute Of New Jersey
195 Little Albany St, 
New Brunswick, NJ 
Accepting New Patients
Expertise in
13
conditions
The Cancer Institute Of New Jersey
195 Little Albany St, 
New Brunswick, NJ 

Overview

Andrew Evens is a Hematologist and an Oncologist in New Brunswick, New Jersey. Dr. Evens is highly rated in 13 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Evens is currently accepting new patients.

His clinical research consists of co-authoring 184 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IL

Hospital Affiliations

Robert Wood Johnson University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

The Cancer Institute of New Jersey
195 Little Albany St, New Brunswick, NJ 08901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma.Big Ten Cancer Research Consortium BTCRC-LYM17-145
Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma.Big Ten Cancer Research Consortium BTCRC-LYM17-145
Enrollment Status: Terminated
Publish Date: September 27, 2024
Intervention Type: Drug
Study Drugs: Copanlisib, Nivolumab, Rituximab
Study Phase: Phase 1
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Procedure, Drug, Radiation, Other, Biological
Study Drugs: Dacarbazine, Doxorubicin, Pembrolizumab, Vinblastine, 18F-Fludeoxyglucose
Study Phase: Phase 2
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Enrollment Status: Unknown
Publish Date: February 21, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: October 26, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas
Enrollment Status: Terminated
Publish Date: September 01, 2021
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

184 Total Publications

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 09, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Matthew Matasar
Hematology | Oncology
Expertise in
26
conditions
Dr. Matthew Matasar
Hematology | Oncology

Rutgers Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (0.1 miles away)
732-475-0824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is a Hematologist and an Oncologist in New Brunswick, New Jersey. Dr. Matasar is highly rated in 26 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Expertise in
32
conditions
Dr. Alison Moskowitz
Hematology | Oncology
Expertise in
32
conditions
Dr. Alison Moskowitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (32.2 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist in New York, New York. Dr. Moskowitz is highly rated in 32 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (32.2 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew Evens

How do I make an appointment with Dr. Andrew Evens?

You can book an appointment with Dr. Andrew Evens by calling their office at 862-445-1542. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew Evens a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew Evens is classified as an Elite expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew Evens specialize in?

While Dr. Andrew Evens is a Hematology, they have specific expertise in Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Andrew Evens participate in research or clinical trials?

Yes. Dr. Andrew Evens has published 184 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Andrew Evens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew Evens accept my insurance?

Dr. Andrew Evens accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 862-445-1542 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Evens's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile